Cytosorbents Corporation (NASDAQ:CTSO) critical care focused immunotherapy firm, is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.09 per share.
For the full year, analysts predict revenues of $ 37.96 million, while looking forward to loss of $ 0.34 per share.
Previous Quarter Performance
Cytosorbents Corporation unwinded loss for the second quarter of $ 0.08 per share, from the revenue of $ 9.80 million. The quarterly revenues improved 57.30 percent compared with the same quarter last year. According to street consensus, CTSO was expected to report 2Q20 loss of $ 0.08 per share from revenue of $ 9.59 million. The top line results outshined analysts by $ 0.21 million or 2.19 percent.
Stock Performance
Shares of Cytosorbents Corporation traded up $ 0.58 or 7.21 percent on Tuesday, reaching $ 8.62 with volume of 443.40 thousand shares. Cytosorbents Corporation has traded high as $ 8.74 and has cracked $ 8.05 on the downward trend
According to the previous trading day, closing price of $ 8.62, representing a 130.37 % increase from the 52 week low of $ 3.49 and a 31.52 % decrease over the 52 week high of $ 11.74.
The company has a market capital of $ 372.02 million and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 17th September 2020, initiated by Jefferies Financial Group at Buy rating, with $ 15.00 target price.
Conference Call
Cytosorbents Corporation will be hosting a conference call at 4:45 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cytosorbents.com
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The companys flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
